Agomelatine
- Generic Name
- Agomelatine
- Brand Names
- Valdoxan
- Drug Type
- Small Molecule
- Chemical Formula
- C15H17NO2
- CAS Number
- 138112-76-2
- Unique Ingredient Identifier
- 137R1N49AD
- Background
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee for Medical...
- Indication
Agomelatine is indicated to treat major depressive episodes in adults.
- Associated Conditions
- Major Depressive Episode
- Associated Therapies
- -
Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 644
- Registration Number
- NCT00467402
- Locations
- 🇺🇸
Novartis Investigative Site, West Allis, Wisconsin, United States
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 501
- Registration Number
- NCT00463242
- Locations
- 🇵🇷
Novartis Investigative Site, Hato Rey, Puerto Rico
The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder
- Conditions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2008-01-08
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT00451490
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 503
- Registration Number
- NCT00411242
- Locations
- 🇺🇸
Novartis Investigative Site, Milwaukee, Wisconsin, United States
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 508
- Registration Number
- NCT00411099
- Locations
- 🇵🇷
Novartis Investigative Site, Rio Piedras, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.